

1. Record Nr.	UNINA9911019280003321
Titolo	Defining optimal immunotherapies for type 1 diabetes // [editors: Gregory Bock and Jamie Goode]
Pubbl/distr/stampa	London, : Novartis Foundation, 2008
ISBN	9786611840525 9781281840523 1281840521 9780470697405 0470697407 9780470697412 0470697415
Descrizione fisica	1 online resource (224 p.)
Collana	Novartis Foundation symposium ; ; v. 292
Disciplina	616.46206
Soggetti	Diabetes - Immunotherapy Diabetes - Treatment
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of

autoimmune diabetes to human; Closing remarks; Contributor index;
Subject index

Sommario/riassunto

This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D). Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials. The book integrates information from human and animal studies. The book considers T1D within the broader context of autoimmune disease. The format contains several discussions, which address specific questions and provides
